bluechiip ltd (asx:bct) · global markets before its parent vision systems was acquired by us based...

©BluechiipLtd|AllRightsReserved


CapitalRaisingPresentation1-for-3Non-renounceableRightsIssueAugust2016

UniquepatentedMEMStechnologycombiningsecurewirelesstrackingwithintegratedtemperaturesensingforextremeenvironments

Bluechiip Ltd (ASX:BCT)F

or p

erso

nal u

se o

nly

©BluechiipLtd|AllRightsReserved 2

DisclaimerMaterial used in this presentation is a summary of available information, and while given in good faith, isprofessional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases andstatutory reports before considering investment in the company.

Certain information may have been derived from third parties and though BCT has no reason to believe that itis not accurate, reliable or complete, it has not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjective judgment and analysis and are subjectto uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT.Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guaranteein relation to this presentation.

BCT reserves right to update, amend or supplement information in this presentation at any time in its absolutediscretion without incurring any obligation to do so.

BluechiipSampleTrackingIntroductionF

or p

erso

nal u

se o

nly

BluechiipSampletrackingforextremeenvironmentsusingMEMSsensors

OverviewIntroduction


• Foundedin2003• ListedonAustralianSecuritiesExchange(ASX)in2011• HeadofficeinMelbourne,Australia• GlobalDistributionNetwork• KeymanufacturingpartnersinEurope,UKand

Malaysia.• OEMPartneringagreementinAssistedReproductive

Technologies(ART)andIVF• StrongIPportfolio– 24grantedpatents,6pendingin

9patentfamilies

TheCompany

For

per

sona

l use

onl

y

4

Corporate overview

CorporateIntroduction


Share PriceTop Shareholders

NumberofShareholders 706 MarketCap.(30Jun‘16) $5.03m

SharePrice(30Jun’16) 2.5c NetCash(30Jun‘16) $0.49m

SharesonIssue(30Jun’16) 201,377,647 EnterpriseValue(30Jun’16) $4.54m

Summary

0

2

4

6

8

10

12

14

16

18

20

0c

1c

2c

3c

4c

5c

6c

7c

8c

9c

10c

Volume(m

illion)

SharePrice

(cent)

PulitanoFamily 9.04%

Dr.Stephen Woodford 7.64%

Chairman&Entities 7.13%

AustralianExecutorTrusteesLimited 5.76%

Roshi BluePtyLtd&Entities 5.09%

Top20Shareholders 49.15%

Founder 2.12%

For

per

sona

l use

onl

y


Our Team

Introduction

Board

Corporate

IainKirkwood AndrewMcLellan MichaelOhanessian

Chairman

Experiencedinvestorandnon-executivedirector(listedandunlisted).Iainhasconsiderablepracticalandoperationalexperiencegainedfromasuccessfulfinancialcareerspanning35yearsincludinginresources,manufacturingandlatterlyhealthcareinAustralia,BritainandtheUSA.IainhasbeenamajorshareholderinBluechiipforover5years.

ManagingDirector

Experiencedininnovationandcommercialisationcombinedwithsignificanttechnicalandoperationalbackground.Andrew hasheldseniorpositionsincludingasVPofBusinessDevelopmentinNorthAmericaandDirectoratLeicaMicrosystems(previouslyVisionBioSystemsadivisionofthepubliclylistedVisionSystems),andasCEOoftheAdvancedManufacturingCo-operativeResearchCentre(AMCRC)

Non-executiveDirector

CEOandManagingDirectorofPraemiumLtd,Michaelbringsexecutiveexperienceintechnology-relatedbusinesses.PreviouslyCEOofVisionBioSystemsMichaelledthetechnologycommercialisationintoglobalmarketsbeforeitsparentVisionSystemswasacquiredbyUSbasedDanaherCorp.Michaelbringsamixtureofoperational,strategicandleadershipcapabilitiestohisroleatBluechiip.

Team

ScottTurner DrIanJohnston IrvinTeoh DavidWhite&HughDouglas

EngineeringManager

ProductEngineeringManager,MEMS(EU)

FinanceManager BusinessDevelopmentNorthAmerica(US)

OscarVal

TechnicalSalesandMarketingManager

For

per

sona

l use

onl

y


Unique patented technology combining secure wireless tracking with integrated temperature sensing for extreme environments

Differentiatedtechnologytolabels,barcodesandRFID

For

per

sona

l use

onl

y

BluechiipSampletrackingforextremeenvironmentsusingMEMSsensors

• Uniquetechnology,superiortolabels,barcodesandRFID

• Operatesreliablydownto-196°C• Instantsampletemperaturesensing• Gammaresistant• Reduceshumanerror• Increasesproductivity• Extremelydifficult tocopy• Applicationsinnichemarkets,e.g.cryogenicstorage

andbiobanking

©Bluechiip Ltd|AllRightsReserved 7

OurProduct:Chip+Reader+Software

OurSolutionTechnologyIntroductionF

or p

erso

nal u

se o

nly

8©Bluechiip Ltd|AllRightsReserved

Core Technology | ChiipMEMSsmartChiip

OurSolutionTechnologyIntroduction

Micro-ElectroMechanicalSystems(MEMS)isamanufacturingtechnologyusedtomakemicrodeviceswithfeatureslessthanthewidthofahumanhair

• FunctionalatCryogenictemperatures(-196oC)

• UniqueIDcodedintoeachChiip atmanufacture

• Providestemperaturewhenpolledbyreader

• Readingtimeunder0.5second,eventhroughfrost

• Gammaresistant

• Canbemolded intoanyplasticMEMSchipsaresuperiortoRFIDinharshenvironmentsMostRFIDtagsuseintegratedcircuit(IC)technologywithelectricalcomponentssensitivetodamagebytemperatureextremesandgammaradiation.MEMSdevicescontainsmicromechanicalcomponentsthatareruggedandabletowithstandexposuretowidetemperaturerangesandgammaradiation.

For

per

sona

l use

onl

y


MarketOpportunities

9

300+millionbiosamples perannum,2+billioninstorage

For

per

sona

l use

onl

y

10©BluechiipLtd|AllRightsReserved

Primary Market Opportunity

MarketStrategy

Cryogenic(-196C°)

Non-cryogenic(-80C°)

Cryogenic biobanking: 680M samples Cryogenic handling: 11M samples

Total biobanking: 2B samples Annual biobanking: 300M samples

Sources:VisualFuseandMarketsandMakets2014

Note:Cryogenicbiobankingisasegmentofthebiobankingmarketwhichstoressamplesatcryogenictemperatures(-196C)forextendedperiods.Themarketisdominatedbyhumansamplesforbiomedicalapplications.

Note:Cryogenictransportreferstosupply,transportandhandlingfromlongtermstoragefacilitiestoapplicationsitesswellasshorttermstorageandmanipulationofsamplesatcryogenictemperatures(e.g.personalisedmedicineandproteincrystallography).

Global Biopreservation Market Greater than $2B in 2015

12,000

10,000

8,000

6,000

4,000

2,000

0

No.ofsam

ples (thousandsperannum

)

Proteincrystallography

Regenerativemedicine

IVFprocedures

Othercryogeniccoldchainlogistics

Totalsamplehandling

7.7%CAGR

2,660

18.5%CAGR

3,100

11.6%CAGR1,800

3,799 11,359

Cryogenictransportandhandling

For

per

sona

l use

onl

y

©Bluechiip Ltd|AllRightsReserved 11

Biobanking today300+millionbiosamples perannum,2+billioninstorage

NeedsBiobanking Today

High volume processing

Dual labelling

Emerging guidelines (ISBER, CAP etc) including temperature

Increasing demand for Cryogenic storage

Iconhere

Iconhere

Iconhere

Iconhere

For

per

sona

l use

onl

y


SegmentsBiobankingToday

IVF Sperm/EggsBloodTissue StemCellPlasma

Biobank tracking technology is not keeping up with the increasing value of biosamples

For

per

sona

l use

onl

y

13©Bluechiip Ltd|AllRightsReserved

Alternative technologies

OurSolutionBiobankingToday

GammaResistant

Cryo safeSurvivesextremetemps

NonvisualIDReadsthroughfrost

On-boardsensorTemperaturesensing

Reducedhumanerror

Productivityimprovements

LABELS BARCODES RFID BLUECHIIP

For

per

sona

l use

onl

y


OurSolution- CryovialsBiobankingToday

Curren

tBiob

ankProcess

Curren

tIssue

s Poorreadabilityinfrost.Labelsunreliable

Notemperaturetrackingsosamplerisk

NotreliableinCryo temps

HumanerrorNotGammaResistant

! ! ! ! ! !

Inefficient

Vial Vialbox Cryo tank Transportdewar Vial&box

!

Blue

chiip

Solutions

GammaResistantImmunetogamma

irradiation(usedforsterilisation)

Cryo safeSurvivesextreme

temps

NonvisualIDReadsthroughfrost

On-boardsensorTemperature

sensing

Reducedhumanerror

+ + + + + +

Productivityimprovements

+

For

per

sona

l use

onl

y


Other addressable markets

AdjacentMarketsStrategy

ColdChainLogisticPharmaceuticals

ColdChainLogisticsFood

IndustrialandManufacturing

Security&Defence

Iconhere

Iconhere

Iconhere

Iconhere

Itemleveltemperaturetrackingofpharmaceuticalsthrough-outthecoldchaincycle.

Itemleveltemperaturetrackingoffrozenandtemperaturesensitivefoodstuffsthrough-outthecoldchaincycle.

Hightemperaturetracking,structuralhealthmonitoring,trackingoftoolsandpartsthatareexposedtoionizingradiationorgammaradiation includingsterilisedmedicaldevices,disposablesandsomefoodproducts.

Anticounterfeitingfashion,foodandhighvaluecommercialitems.Cloningabluechiip®tagisextremelydifficult.trackingoftoolsandpartsthatareexposedto ionizingradiation,securityanddefense.

For

per

sona

l use

onl

y


Strategic Progress and Sales Pipeline

16

For

per

sona

l use

onl

y


Embedded solutions for OEM partners

PartneringStrategy

Service & SupportGlobal support services

Design IntegrationCustom design and solution definition

ReaderCustomisable Hardware

Software & ElectronicsIntegrated into partner products

BluechiipsSuitable for various formats

For

per

sona

l use

onl

y


Genea Biomedx License & Supply Agreement

OEMPartneringStrategyF

or p

erso

nal u

se o

nly


Bluechiip IVF Transport CoolerActive ID and Temperature Recording in Liquid Nitrogen -196oC

ProductsStrategyF

or p

erso

nal u

se o

nly

1,800,000

2,500,000

3,000,000

3,700,000

15,000,000

7,500,000

IVF PROTEINCRYSTALLOGRAPHY

REGENERATIVEMEDICINE OTHERCRYOANDTRANSPORT

GENERALBIOBANKING GENERALBIOBANKING-NEXTGENERATIONCHIPS

NUMBE

ROFUNITS

Annualconsumables(Chiips) Storedconsumables

High Value Target Markets

MarketsSalesPipeline


Bluechiip Opportunity(USD) $20m+ $2.5M+ $30M+ $30M+ $200M+

OEMPIPELINECLIENTS

AgreementDec2015RevenueMar2016DisplayedJuly‘16TargetLaunchQ1‘17

ExecutedagreementEvaluationinprogressValidationCustomers

ExecutedagreementEvaluationinprogressValidationcustomers

Evaluationagreements&developerkitsinprogress

Developerkitssoldwithmultiplevendors& validationcustomers

R&DDevelopment.Highvalueovertemperaturesensors

300M

2B

300M

$1.5B+

33M

Bluechiipopportunity($US)

For

per

sona

l use

onl

y


Our Sales

OurCustomersSalesPipeline

CASE STUDY:

METHODBluechiip tracking devices were attached to five cryocytecryopreservation bags.

All bags were transferred to a cryogenic storage tank. Each bag underwent five consecutive freeze-thaw steps.

RESULTSAll bags were successfully identified without the need to manually lift and visually check the patient identification label.

The Bluechiip tracking technology provided localised temperature information during the retrieval process.Faster and more consistent search times compared to manual methods.

Bags were maintained in more ideal, less disrupted conditions compared to manual methods.

For

per

sona

l use

onl

y

Targeted Sales & Pipeline Progress

Market


Target Market MarketSizebySamples Bluechiip OpportunityUSD(Licencefee’s,R&D services,Bluechiips &Readers)

OEMPartner Progress>15partnersinpipeline

Timing

AssistedReproductiveTechnology(IVF)

1.8m IVFCycles/yr,33msamplesinstorage

$20m+ DeveloperKitDeliveredSupply AgreementExecutedDueDiligenceComplete- LicenceFeereceivedTradeshowdemonstration– R&DFeereceivedTargetLaunchQ1‘17

July‘15Dec ‘15Mar’16July‘16Q1‘17

ProteinCrystallography

2.5mSamples/yr $2.5m+ ExecutedagreementanddeliveryoftrialkitEvaluationinprogressEndValidationCustomersinplace

Q4‘15

RegenerativeMedicine

3msamples/yr15m+instorage

$30-50m+ ExecutedagreementanddeliveryoftrialkitEvaluationinprogressValidationcustomers

Q4‘15

Othercryogeniccoldchainlogistics

3.5-7.5msamples/yr>250minstorage

$30m+ Multiple evaluationagreementsDeveloperkitsdelivered

Q1-3 ‘16

GeneralBiobanking 300m+samples/yr>2B instorage

$200m+ DeveloperkitssoldwithmultiplevendorsEnd validationcustomersales

FutureCore TechnologyandAdjacentMarketOpportunitiesHighvalueovertemperaturesensors

300m+ $1.5B+ Governmentco-fundedR&DDevelopment

Engagement(Non-DisclosureAgreement)

Saleofdeveloper/trialkit,

evaluationagreement

Development&Supplyagreement

Demonstrationinmarket

Commercialproduct“Bluechiip Inside”

SalesPipelineF

or p

erso

nal u

se o

nly


Product Pipeline - Readers

ProductsStrategyF

or p

erso

nal u

se o

nly


Use of Proceeds

25

The proceeds raised from the Offer will be used to:

ü Complete development of products in Assisted Reproductive Technologies Market with our first OEM partner Genea Biomedx;

ü Complete current evaluation and development trials with pipeline customers in USA, EU and Asia;

ü Launch and roll-out the first range of IVF products through partners; and

ü Corporate overheads.

For

per

sona

l use

onl

y


Investment HighlightsØ Unique patented technology combining secure wireless tracking with integrated temperature

sensing for extreme environmentsØ $2b+ bio-preservation/bio-storage target marketØ Executed supply agreement with Genea Biomedx in the high value IVF market with global

distribution through a major pharmaceuticals companyØ Repeat initial revenue from license fees, service and product sales (2nd half FY16 $150k); Ø Pipeline of over 15 partners with initial revenue from developer kits and validation customersØ High revenue growth expected in short to medium term on IVF product release early 2017Ø Trial and developer agreements in protein crystallography, cell therapies, general biobanking

and Auto Identification and Data Capture marketsØ Government co-funded projects with University of Melbourne & Swinburne University to

make Bluechiips adaptable and suitable for formats with significant value enhancementØ Large adjacent market opportunitiesF

or p

erso

nal u

se o

nly


Summary of Rights Issue

27

A summary of the key information in respect of the Rights Issue is shown in the table below. Shareholders should read the Offer Booklet in its entirety before deciding to participate in the Rights Issue.

Ratio: One New Share for every three existing ordinary Shares (Non-renounceable)

Issue Price: $0.0225 per share

Number of New Shares: 67,125,882

Gross Proceeds: $1,510,000 (If fully subscribed)

For

per

sona

l use

onl

y


Summary of Rights Issue

28

KEY DATES (INDICATIVE)

15 August 2016 Announcement DateAppendix 3B lodged with ASX

19 August 2016 Ex Date

22 August 2016 Record Date

25 August 2016 Dispatch of offer documentsRights Issue opens

9 September 2016 Rights Issue Closing Date

14 September 2016 Shortfall Notification Date

16 September 2016 Settlement Date

For

per

sona

l use

onl

y

Needhi-resimage

Contact



AndrewMcLellan,ManagingDirector&CEOTel:+61(0)397639763Mob:+61(0)457823470Email:[email protected]

For

per

sona

l use

onl

y

bluechiip ltd (asx:bct) · global markets before its parent vision systems was acquired by us based...

Documents